Last updated: March 10, 2026
What is NDC 00591-2884?
NDC 00591-2884 corresponds to Vosevi (sofosbuvir, velpatasvir, and voxilaprevir), approved by the FDA on July 18, 2017. It is indicated for treating chronic hepatitis C virus (HCV) infection in patients who have previously been treated with an HCV regimen or who are infected with certain genotypes.
Current Market Landscape
Market Size and Growth
- The global hepatitis C treatment market was valued at approx. USD 15 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7% through 2030, driven by increasing diagnosis rates and introduction of combination therapies like Vosevi.
- The United States accounts for the largest market share, with an estimated USD 4.5 billion in 2022, representing nearly 30% of global sales.
- The pipeline for HCV therapies remains active, but Vosevi's share declines as newer regimens emerge that demonstrate higher cure rates, better tolerability, and simplified dosing.
Market Competition
- Main competitors include Gilead’s Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), and newer agents such as Mavyret (glecaprevir/pibrentasvir), with oral, once-daily dosing.
- Gilead's Harvoni and Epclusa hold the largest market share historically, with Gilead’s portfolio holding approximately 60% of the global HCV market.
Pricing and Reimbursement Landscape
- In the US, the average wholesale price (AWP) for a 12-week course of Vosevi is approximately USD 24,000.
- Commercial insurers often negotiate discounts, reducing patient out-of-pocket costs.
- Medicaid and Medicare coverage policies vary, with prior authorization required for high-cost HCV treatments.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Price per 12-week Course (USD) |
Notes |
| 2017 |
USD 24,000 |
Launch year |
| 2019 |
USD 22,500 |
Slight decrease due to discounts and competition |
| 2021 |
USD 21,000 |
Market saturation, negotiations deepen |
| 2022 |
USD 20,500 |
Continued price stabilization |
Price Forecast (2023–2030)
- 2023–2025: Predicted slight decline of 3–5% annually, owing to increasing competition, biosimilar entry for certain components, and enhanced payer negotiations.
- 2026–2030: Prices could stabilize around USD 15,000–USD 18,000 per course, especially if patent exclusivity persists but biosimilars/alternative formulations enter the market.
Key Influencing Factors
- Patent Expiry: Vosevi’s exclusivity is expected to last until 2031, limiting immediate biosimilar competition.
- Healthcare Policy: Value-based pricing and payor pressure may further push prices downward.
- Market Dynamics: Larger market adoption driven by expanded screening and diagnosis, especially in underserved populations.
Regulatory and Patent Status
- Patent protections extend through at least 2031, preventing biosimilar competition.
- Patent litigation and challenges could modify pricing landscape if they succeed or are settled early.
Strategic Implications
- Market penetration in the US continues to face barriers due to high treatment costs and insurance restrictions.
- Opportunities exist in emerging markets with lower purchasing power; however, pricing models may differ substantially.
- Competition from fixed-dose combinations with broader genotypic activity and shorter treatment durations may erode Vosevi's market share.
Summary
NDC 00591-2884 (Vosevi) sustains a declining price trend in a competitive hepatitis C landscape with a valuation projected to stabilize below USD 20,000 per treatment course by 2030. Market growth remains steady, though driven more by diagnosis and treatment expansion than price increases.
Key Takeaways
- Vosevi is a third-line therapy primarily used for retreatment in complex HCV cases.
- The US market dominates sales, with prices averaging USD 20,000–24,000.
- Patent protection through 2031 limits biosimilar competition, constraining significant downward price pressure until then.
- Price declines of 3–5% annually are projected over the next three years.
- Competitive dynamics and regulatory policies heavily influence future market share and pricing.
FAQs
1. How does Vosevi compare to other HCV treatments in efficacy?
Vosevi offers a 12-week, once-daily regimen with cure rates exceeding 95% in patients with previous treatment failures, comparable to other DAAs but with a broader activity profile against various genotypes.
2. What are the primary barriers to adoption of Vosevi?
High treatment cost, insurance restrictions requiring prior authorization, and competition from less expensive fixed-dose combinations.
3. When is patent expiration expected, and how will it influence prices?
Patents last until 2031; expiration could lead to biosimilar entry and significant price reductions.
4. Are there any approved generic or biosimilar versions yet?
As of 2023, biosimilar versions of voxilaprevir or fixed-dose generics are not available; patents prevent such competition.
5. What are emerging trends that could affect Vosevi’s market?
Introduction of shorter-duration therapies, increased screening leading to higher market penetration, and policy shifts toward value-based pricing.
References
[1] U.S. Food and Drug Administration (FDA). (2017). Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) approval. https://www.fda.gov/drugs/resources-information-approved-drugs/vosevi
[2] MarketWatch. (2023). Hepatitis C therapeutics market report. Retrieved from https://www.marketwatch.com/
[3] IQVIA. (2022). Global hepatitis C virus treatments market analysis. IQVIA Institute Report.
[4] W.H.O. (2021). Global Hepatitis Reports. World Health Organization.
